.png){kind=icon}
.png){kind=icon}
Return
Advances in Novel Therapeutics for Idiopathic Pulmonary Fibrosis
.png){kind=icon}
PRE
AI
M
B
X
T
X
DOI：10.1016/j.pupt.2025.102396.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
IPF is a chronic, progressive interstitial lung disease characterized by irreversible lung scarring, leading to exertional dyspnea and a gradual decline in pulmonary function. Its pathogenesis involves multiple mechanisms, including chronic inflammation, aberrant cytokine signaling, and alveolar epithelial injury. Currently, IPF remains incurable, and treatment primarily aims to slow disease progression and improve survival. This paper systematically reviews recent clinical trials of novel IPF drug therapies that have demonstrated promising efficacy, aiming to inform future drug development.
Journal
P
IF:
2.8
Papers:
2.1K
Citations:
2.6K
Organization
Cited Papers